Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Gastrointestinal 8Genitourinary 7Breast 6Dermatologic 5Thoracic 4Other hematologic neoplasm 2Head & Neck 2Plasma cell 1Other neoplasm 1Other 1Myeloid 1Lymphoid 1Gynecologic 1

Conditions

Leukemia, Myeloid, Acute 3510Precursor Cell Lymphoblastic Leukemia-Lymphoma 2499Leukemia 2362Leukemia, Lymphocytic, Chronic, B-Cell 1992Myelodysplastic Syndromes 1412Hematologic Neoplasms 1385Lymphoma 1176Lymphoma, Non-Hodgkin 1079Leukemia, Myelogenous, Chronic, BCR-ABL Positive 863Lymphoma, Follicular 761Multiple Myeloma 739Lymphoma, Mantle-Cell 730Lymphoma, Large B-Cell, Diffuse 714Burkitt Lymphoma 692Lymphoma, B-Cell, Marginal Zone 645Hodgkin Disease 636Recurrence 627Leukemia, Myelomonocytic, Chronic 536Neoplasms 519Lymphoma, Large-Cell, Immunoblastic 451Myeloproliferative Disorders 445Leukemia, Myeloid, Chronic-Phase 437Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 414Congenital Abnormalities 411Waldenstrom Macroglobulinemia 360Blast Crisis 353Leukemia, Myeloid, Accelerated Phase 318Lymphoma, T-Cell, Cutaneous 311Primary Myelofibrosis 297Neoplasms, Plasma Cell 276

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Patient Preference × Other hematologic neoplasm × Clear all
NCT06125795 2026-05-01

PROVIDENCE

AbbVie

Active not recruiting
146 enrolled
LymphoidOther hematologic neoplasm

Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Patient Preference

NCT05883956 2025-03-20

PREFER-HMA

Otsuka Australia Pharmaceutical Pty Ltd

Phase 3 Active not recruiting
13 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Patient Preference

Data powered by HemOnc (CC BY 4.0) Colophon âš¡